Two Sigma Securities’s Scinai Immunotherapeutics SCNI Stock Holding History

Two Sigma Securities’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,470	Closed	-$18.6K	–	1948
2025 Q3	$18.6K	Buy	+1,470	New	+$25.6K	﹤0.01%	1150
2022 Q2	–	Sell	-23	Closed	-$38K	–	2776
2022 Q1	$38K	Sell	23 -26	-53%	-$37.7K	﹤0.01%	1908
2021 Q4	$116K	Buy	+49	New	+$101K	0.01%	1159

Other funds holding SCNI

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $187B AUM 21.7% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Securities's SCNI Position: Q4 2025 in Review

Two Sigma Securities sold out of Scinai Immunotherapeutics (SCNI) in Q4 2025, closing a stake of 1,470 shares — an estimated $18.6K sold.

Two Sigma Securities first reported a position in SCNI in Q4 2021 and held it in 3 quarters. The position peaked at $116K in Q4 2021. 7 funds tracked by Wall St. Rank hold SCNI as of Q4 2025.

Two Sigma Securities reported no remaining Scinai Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
Two Sigma Securities sold 1,470 Scinai Immunotherapeutics shares in Q4 2025, an estimated $18.6K.
Two Sigma Securities first reported a position in Scinai Immunotherapeutics in Q4 2021 and held it in 3 quarters.
Two Sigma Securities's Scinai Immunotherapeutics position peaked at $116K in Q4 2021.
7 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q4 2025.

Based on Two Sigma Securities's 13F filing for Q4 2025, filed 17 Feb 2026.